Healthcare Aug 20, 2020 12:08 PM (GMT+8) · EqualOcean
Bellen Chemistry, a high-end chemical drug developer, announced to close the Series D+ fundraising. HighLight Capital led the investment, participated by Kunlun Capital and Yantai Jinye Investment. It is a contract research/development and manufacturing organization (CRO/CDMO) that focuses on small molecules. The bankroll will help the company continue the infrastructure platform for new drug discovery and chemosynthesis.